AR087281A1 - Anticuerpo monoclonal de interleucina-31 - Google Patents
Anticuerpo monoclonal de interleucina-31Info
- Publication number
- AR087281A1 AR087281A1 ARP120102662A ARP120102662A AR087281A1 AR 087281 A1 AR087281 A1 AR 087281A1 AR P120102662 A ARP120102662 A AR P120102662A AR P120102662 A ARP120102662 A AR P120102662A AR 087281 A1 AR087281 A1 AR 087281A1
- Authority
- AR
- Argentina
- Prior art keywords
- interleucine
- monoclonal antibody
- feline
- canine
- specifically binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un anticuerpo aislado que se enlaza de manera específica a por lo menos una de lnterleucina-31 (IL-31) canina o IL-31 felina. Dichos anticuerpos pueden estar en la forma de composiciones de diagnóstico y/o veterinarias útiles para tratar una condición de prurito y/o de alergia en perros o gatos.Reivindicación 1: Un anticuerpo aislado caracterizado porque se enlaza de manera específica a por lo menos una de una IL-31 canina o una IL-31 felina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161510268P | 2011-07-21 | 2011-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087281A1 true AR087281A1 (es) | 2014-03-12 |
Family
ID=46704979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102662A AR087281A1 (es) | 2011-07-21 | 2012-07-20 | Anticuerpo monoclonal de interleucina-31 |
Country Status (24)
Country | Link |
---|---|
US (6) | US8790651B2 (es) |
EP (4) | EP3842456A1 (es) |
JP (1) | JP6022563B2 (es) |
KR (2) | KR101613024B1 (es) |
CN (2) | CN105504059B (es) |
AR (1) | AR087281A1 (es) |
AU (2) | AU2012285432C1 (es) |
BR (1) | BR112014001407A8 (es) |
CA (2) | CA2926379A1 (es) |
CY (2) | CY1119475T1 (es) |
DK (1) | DK2734549T3 (es) |
ES (2) | ES2638340T3 (es) |
HR (2) | HRP20171198T1 (es) |
HU (2) | HUE034282T2 (es) |
LT (2) | LT2734549T (es) |
ME (1) | ME02837B (es) |
MX (1) | MX349053B (es) |
PL (2) | PL2734549T3 (es) |
PT (2) | PT2734549T (es) |
RS (2) | RS56268B1 (es) |
SI (2) | SI2734549T1 (es) |
UY (1) | UY34206A (es) |
WO (1) | WO2013011407A1 (es) |
ZA (1) | ZA201400768B (es) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101329843B1 (ko) * | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
EP3345607B1 (en) | 2006-12-29 | 2022-10-26 | Ossifi-Mab LLC | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
EP3248617A3 (en) * | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
HUE036548T2 (hu) | 2007-12-07 | 2018-08-28 | Zymogenetics Inc | IL-31-re specifikus humanizált antitest molekulák |
BR112012028920B1 (pt) * | 2010-05-14 | 2021-03-23 | Amgen Inc. | Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína |
RU2663123C2 (ru) * | 2010-11-30 | 2018-08-01 | Чугаи Сейяку Кабусики Кайся | Индуцирующий цитотоксичность терапевтический агент |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
TR201816416T4 (tr) | 2012-08-21 | 2018-11-21 | Janssen Pharmaceutica Nv | Risperidona yönelik antikorlar ve bunların kullanımı. |
CA2882490A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc. | Antibodies to paliperidone and use thereof |
EP3590537A1 (en) * | 2012-09-26 | 2020-01-08 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
US9499621B2 (en) * | 2013-04-08 | 2016-11-22 | Cytodyn, Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
AU2014346770B2 (en) * | 2013-11-06 | 2020-05-21 | Janssen Biotech, Inc. | Anti-CCL17 antibodies |
US11072647B2 (en) * | 2013-12-19 | 2021-07-27 | Onsejo Nacional DE Investigation Cientiticay Tecnica | TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro |
CA2932515C (en) * | 2013-12-20 | 2023-08-01 | Intervet International B.V. | Caninized antibodies |
ES2923641T3 (es) * | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
WO2015120138A2 (en) * | 2014-02-05 | 2015-08-13 | Dana-Farber Cancer Institute, Inc. | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF |
EP3102599B1 (en) * | 2014-02-06 | 2019-02-27 | ARSANIS Biosciences GmbH | E. coli specific antibody sequences |
HRP20231514T1 (hr) | 2014-03-26 | 2024-03-01 | Julius-Maximilians-Universität Würzburg | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka |
WO2015196142A1 (en) * | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
CN106999577B (zh) * | 2014-07-16 | 2021-12-21 | 特兰斯吉恩股份有限公司 | 溶瘤病毒和免疫检查点调节因子组合 |
WO2016075612A1 (en) * | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
WO2016104657A1 (ja) * | 2014-12-26 | 2016-06-30 | 橋本 正 | 癌治療剤 |
BR112017015661A2 (pt) | 2015-01-30 | 2018-03-20 | Saitama Medical University | anticorpo anti-alk2 |
CN107921104A (zh) * | 2015-02-22 | 2018-04-17 | 索伦托治疗有限公司 | 结合cd137的抗体疗法 |
BR112017020955A2 (pt) * | 2015-03-31 | 2018-07-10 | Medimmune Limited | forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos |
KR102514173B1 (ko) * | 2015-04-14 | 2023-03-27 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
CA2980992C (en) | 2015-04-14 | 2024-01-23 | Akihisa Kaneko | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
US11424061B2 (en) * | 2015-04-14 | 2022-08-23 | Hanchett Entry Systems, Inc. | Solenoid assembly actuation using resonant frequency current controller circuit |
JP2018516248A (ja) | 2015-05-29 | 2018-06-21 | アンフィヴェナ セラピューティクス,インク. | 二重特異性のcd33およびcd3結合タンパク質を使用する方法 |
CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
BR112018009064A8 (pt) * | 2015-11-17 | 2019-02-26 | Jiangsu Hengrui Medicine Co | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo |
CA3008809A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
US20190023786A1 (en) * | 2016-01-12 | 2019-01-24 | Palleon Pharmaceuticals Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
BR112018071965A2 (pt) * | 2016-04-27 | 2019-03-06 | Benchmark Animal Health Ltd | tratamento da dermatite atópica canina |
CN107474134B (zh) * | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
KR102492057B1 (ko) * | 2016-06-15 | 2023-01-26 | 노파르티스 아게 | 골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법 |
SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
CN110035769A (zh) * | 2016-09-21 | 2019-07-19 | 奈斯科尔公司 | 针对siglec-15的抗体及其使用方法 |
CA3043365A1 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
JP7127859B2 (ja) | 2016-11-09 | 2022-08-30 | ノース カロライナ ステート ユニバーシティ | キメラタンパク質を用いたアレルギー疾患の治療 |
BR112019012731A2 (pt) * | 2016-12-21 | 2019-11-26 | Mereo Biopharma 3 Ltd | uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita |
US11680101B2 (en) * | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
EP3582813A4 (en) * | 2017-02-16 | 2020-12-30 | XBiotech, Inc | TREATMENT OF SUPPURATIVE HIDRADENITIS |
WO2018156250A1 (en) * | 2017-02-21 | 2018-08-30 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
JP7314115B2 (ja) * | 2017-03-31 | 2023-07-25 | セレクティス ソシエテ アノニム | ユニバーサル抗cd22キメラ抗原受容体操作免疫細胞 |
EP3609922A2 (en) * | 2017-04-13 | 2020-02-19 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
EP3630824A1 (en) * | 2017-05-26 | 2020-04-08 | GlaxoSmithKline Intellectual Property Development Ltd | Biopharmaceutical compositions and related methods |
WO2018219327A1 (zh) * | 2017-06-01 | 2018-12-06 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
TWI726228B (zh) * | 2017-08-09 | 2021-05-01 | 國立臺灣大學 | Cd14拮抗分子用於治療癌症 |
SG11201913969SA (en) * | 2017-08-16 | 2020-01-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1 |
JP7226833B2 (ja) * | 2017-09-21 | 2023-02-21 | イムチェック セラピューティクス エスエーエス | Btn2に特異性を有する抗体及びその使用 |
RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
WO2019086694A1 (en) | 2017-11-06 | 2019-05-09 | Geert Mudde | Il31 antigen and vaccine |
WO2019104157A1 (en) * | 2017-11-21 | 2019-05-31 | The University Of Vermont And State Agricultural College | Highly specific zika neutralizing human antibodies |
KR20210009296A (ko) * | 2017-12-11 | 2021-01-26 | 유비아이 아이피 홀딩스 | 아토피성 피부염의 치료 및/또는 예방을 위한 il-31의 펩타이드 면역원 및 이의 제형물 |
MA51289A (fr) | 2017-12-18 | 2021-03-24 | Regeneron Pharma | Molécules de liaison à l'antigène bispécifiques se liant au récepteur de la leptine et/ou à gp130, et leurs procédés d'utilisation |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
EP3749353A1 (en) * | 2018-02-09 | 2020-12-16 | Nestlé Skin Health SA | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
AU2019236328A1 (en) | 2018-03-16 | 2020-09-10 | Zoetis Services Llc | Peptide vaccines against Interleukin-31 |
CA3093539A1 (en) * | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
EP3770262A4 (en) * | 2018-03-16 | 2021-12-15 | National University Corporation Shiga University of Medical Science | ANTIBODY FRAGMENT DEGRADING AND ELIMINATING ABNORMAL TDP-43 |
US11608381B2 (en) * | 2018-04-06 | 2023-03-21 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
WO2019216675A1 (ko) * | 2018-05-09 | 2019-11-14 | 주식회사 굳티셀 | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 |
EP3806885A2 (en) * | 2018-06-13 | 2021-04-21 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類pd-l1之抗體及其用途 |
TWI803682B (zh) * | 2018-08-20 | 2023-06-01 | 美商輝瑞股份有限公司 | 抗-gdf15抗體、組成物及使用方法 |
US20220267428A1 (en) * | 2018-10-10 | 2022-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS |
CA3120474A1 (en) * | 2018-12-21 | 2020-06-25 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
MA54657A (fr) * | 2019-01-03 | 2021-11-10 | Invetx Inc | Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation |
AU2020240132A1 (en) * | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
EP3947441A1 (en) * | 2019-03-27 | 2022-02-09 | UMC Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
EP3962936A1 (en) * | 2019-05-03 | 2022-03-09 | Singapore Health Services Pte. Ltd. | Treatment and prevention of metabolic diseases |
CN110283246A (zh) * | 2019-06-20 | 2019-09-27 | 长春西诺生物科技有限公司 | 一种抗猫细小病毒的猫源化基因工程抗体 |
US11890353B2 (en) * | 2019-10-15 | 2024-02-06 | Northwestern University | Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies |
BR112022006590A2 (pt) * | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | Preparação contendo anticorpos |
EP4077380A1 (en) | 2019-12-20 | 2022-10-26 | Intervet International B.V. | Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis |
CA3162031A1 (en) | 2019-12-20 | 2021-06-24 | Mohamad Morsey | Canine interleukin-4 receptor alpha antibodies |
WO2021207242A2 (en) * | 2020-04-07 | 2021-10-14 | Fred Hutchinson Cancer Research Center | Anti-mesothelin antigen-binding molecules and uses thereof |
US20230242635A1 (en) | 2020-04-17 | 2023-08-03 | Zoetis Services Llc | Canine antibody variants |
JP2023522030A (ja) * | 2020-04-17 | 2023-05-26 | ゾエティス・サービシーズ・エルエルシー | ネコ科動物抗体バリアント |
BR112022021450A2 (pt) * | 2020-04-24 | 2022-12-27 | Millennium Pharm Inc | O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada |
TWI800824B (zh) * | 2020-05-08 | 2023-05-01 | 大陸商亘喜生物科技(上海)有限公司 | 一種抗cd19抗體的抗體及其製備和應用 |
US11434276B2 (en) | 2020-05-11 | 2022-09-06 | Invetx, Inc. | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use |
IL298257A (en) * | 2020-05-22 | 2023-01-01 | Regeneron Pharma | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
MX2023001490A (es) * | 2020-08-05 | 2023-04-27 | Synthekine Inc | Moleculas de union a il27r\03b1 y metodos de uso. |
GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
AU2021327387A1 (en) * | 2020-08-21 | 2023-05-04 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
FR3113458B1 (fr) | 2020-08-21 | 2022-10-14 | Purally | Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie |
IL301413A (en) | 2020-09-28 | 2023-05-01 | Zoetis Services Llc | Canine antibody variants |
PE20240110A1 (es) | 2020-09-29 | 2024-01-22 | Zoetis Services Llc | Variantes de anticuerpos felinos |
WO2022079139A1 (en) * | 2020-10-15 | 2022-04-21 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha |
TW202221039A (zh) | 2020-10-19 | 2022-06-01 | 美商碩騰服務公司 | 犬及貓抑瘤素M受體β之抗體及其用途 |
WO2022094009A1 (en) * | 2020-10-30 | 2022-05-05 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies to sars-cov-2 nucleocapsid protein |
EP4247848A1 (en) * | 2020-11-23 | 2023-09-27 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
EP4263596A1 (en) * | 2020-12-18 | 2023-10-25 | Zoetis Services LLC | Mutations in feline antibody constant regions |
KR20230136604A (ko) | 2021-01-28 | 2023-09-26 | 조에티스 서비시즈 엘엘씨 | 개과 항체 불변 영역에서의 돌연변이 |
EP4284830A1 (en) | 2021-01-29 | 2023-12-06 | Bayer Animal Health GmbH | Vaccine composition for breaking self-tolerance |
AU2022223713A1 (en) | 2021-02-22 | 2023-09-07 | Zoetis Services Llc | Horse il-31 induced pruritus model |
IL305828A (en) * | 2021-03-22 | 2023-11-01 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of using them |
US20220348659A1 (en) * | 2021-03-24 | 2022-11-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
AU2022260544A1 (en) * | 2021-04-23 | 2023-11-30 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
CA3227725A1 (en) | 2021-08-20 | 2023-02-23 | Mohamad Morsey | Homodimer fusion proteins for treating atopic dermatitis |
WO2023111128A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha ii |
WO2023152486A1 (en) | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
WO2024057096A1 (en) | 2022-09-14 | 2024-03-21 | Ceva Sante Animale | Treatment of atopic dermatitis using self-replicating rna expressing il-31 |
CN115505575B (zh) * | 2022-11-16 | 2023-03-24 | 中国科学院天津工业生物技术研究所 | 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5350576A (en) | 1991-09-13 | 1994-09-27 | Mycogen Corporation | Bacillus thuringiensis isolates for controlling acarides |
US6194167B1 (en) | 1997-02-18 | 2001-02-27 | Washington State University Research Foundation | ω-3 fatty acid desaturase |
WO1999061618A2 (en) * | 1998-05-29 | 1999-12-02 | Heska Corporation | Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof |
EP1161530B1 (en) | 1999-03-18 | 2005-05-18 | MERCK PATENT GmbH | Protein for blocking platelet adhesion |
US6790639B2 (en) | 2000-02-29 | 2004-09-14 | Pfizer Inc. | Mammalian osteoregulins |
CN100455599C (zh) * | 2000-03-03 | 2009-01-28 | 协和发酵工业株式会社 | 基因重组抗体及其抗体片段 |
KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
US6818444B2 (en) * | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
EP1485126A4 (en) * | 2001-12-21 | 2007-03-21 | Idexx Lab Inc | DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE |
CN100575482C (zh) | 2002-01-18 | 2009-12-30 | 津莫吉尼蒂克斯公司 | 新的细胞因子zcytor17配体 |
US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
KR20060015602A (ko) * | 2003-05-31 | 2006-02-17 | 마이크로메트 에이지 | EpCAM 에 대한 이중 특이성 항체를 포함하는약학조성물 |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
ES2579758T3 (es) | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
WO2006088955A2 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
US20060182743A1 (en) | 2005-02-14 | 2006-08-17 | Janine Bilsborough | Methods of treating skin disorders using an IL-31RA antagonist |
JP2008535823A (ja) * | 2005-03-25 | 2008-09-04 | キュラジェン コーポレイション | テネイシンの主要な抗原に対する抗体 |
US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
CN101198624B (zh) | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
AU2007249713A1 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists |
JP5230022B2 (ja) * | 2006-08-09 | 2013-07-10 | ベイラー リサーチ インスティテュート | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
EP2759549B1 (en) | 2006-09-01 | 2015-08-19 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
JP5238710B2 (ja) | 2006-10-19 | 2013-07-17 | シーエスエル、リミテッド | インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト |
HUE036548T2 (hu) | 2007-12-07 | 2018-08-28 | Zymogenetics Inc | IL-31-re specifikus humanizált antitest molekulák |
PT2384326E (pt) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
EP2331579B1 (en) | 2008-09-04 | 2017-07-05 | Vet Therapeutics, Inc. | Monoclonal antibodies |
WO2011065935A1 (en) | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
MX2012004415A (es) | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
KR20220017432A (ko) | 2010-02-24 | 2022-02-11 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
EP2644698B1 (en) | 2010-11-17 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
WO2013014105A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Biologicals S.A. | Prame purification |
CA3093539A1 (en) * | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
-
2012
- 2012-06-28 US US13/536,081 patent/US8790651B2/en active Active
- 2012-07-05 ES ES12748547.2T patent/ES2638340T3/es active Active
- 2012-07-05 HU HUE12748547A patent/HUE034282T2/en unknown
- 2012-07-05 KR KR1020147004364A patent/KR101613024B1/ko active IP Right Grant
- 2012-07-05 AU AU2012285432A patent/AU2012285432C1/en active Active
- 2012-07-05 EP EP20194926.0A patent/EP3842456A1/en active Pending
- 2012-07-05 PL PL12748547T patent/PL2734549T3/pl unknown
- 2012-07-05 LT LTEP12748547.2T patent/LT2734549T/lt unknown
- 2012-07-05 PT PT127485472T patent/PT2734549T/pt unknown
- 2012-07-05 BR BR112014001407A patent/BR112014001407A8/pt not_active Application Discontinuation
- 2012-07-05 EP EP17168574.6A patent/EP3219729B1/en active Active
- 2012-07-05 CN CN201610117883.3A patent/CN105504059B/zh active Active
- 2012-07-05 RS RS20170846A patent/RS56268B1/sr unknown
- 2012-07-05 ME MEP-2017-192A patent/ME02837B/me unknown
- 2012-07-05 SI SI201231038T patent/SI2734549T1/sl unknown
- 2012-07-05 KR KR1020167004578A patent/KR101742928B1/ko active IP Right Review Request
- 2012-07-05 CN CN201280046131.2A patent/CN103890009B/zh active Active
- 2012-07-05 CA CA2926379A patent/CA2926379A1/en not_active Abandoned
- 2012-07-05 PT PT171685746T patent/PT3219729T/pt unknown
- 2012-07-05 MX MX2014000803A patent/MX349053B/es active IP Right Grant
- 2012-07-05 WO PCT/IB2012/053450 patent/WO2013011407A1/en active Application Filing
- 2012-07-05 RS RS20201227A patent/RS60924B1/sr unknown
- 2012-07-05 SI SI201231847T patent/SI3219729T1/sl unknown
- 2012-07-05 LT LTEP17168574.6T patent/LT3219729T/lt unknown
- 2012-07-05 ES ES17168574T patent/ES2827231T3/es active Active
- 2012-07-05 HU HUE17168574A patent/HUE051068T2/hu unknown
- 2012-07-05 CA CA2842475A patent/CA2842475C/en active Active
- 2012-07-05 DK DK12748547.2T patent/DK2734549T3/en active
- 2012-07-05 EP EP12748547.2A patent/EP2734549B1/en not_active Revoked
- 2012-07-05 JP JP2014520753A patent/JP6022563B2/ja active Active
- 2012-07-05 PL PL17168574T patent/PL3219729T3/pl unknown
- 2012-07-05 EP EP19196963.3A patent/EP3653645A1/en active Pending
- 2012-07-20 AR ARP120102662A patent/AR087281A1/es active IP Right Grant
- 2012-07-20 UY UY0001034206A patent/UY34206A/es active IP Right Grant
-
2014
- 2014-01-31 ZA ZA2014/00768A patent/ZA201400768B/en unknown
- 2014-06-12 US US14/302,730 patent/US20140286958A1/en not_active Abandoned
- 2014-07-08 US US14/325,541 patent/US9206253B2/en active Active
-
2016
- 2016-05-30 AU AU2016203590A patent/AU2016203590B2/en active Active
-
2017
- 2017-08-03 HR HRP20171198TT patent/HRP20171198T1/hr unknown
- 2017-08-24 CY CY20171100897T patent/CY1119475T1/el unknown
-
2018
- 2018-12-05 US US16/210,228 patent/US10421807B2/en active Active
-
2019
- 2019-08-13 US US16/539,455 patent/US20190389944A1/en active Pending
- 2019-08-14 US US16/540,483 patent/US10526405B2/en active Active
-
2020
- 2020-10-09 HR HRP20201634TT patent/HRP20201634T1/hr unknown
- 2020-11-13 CY CY20201101077T patent/CY1123791T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087281A1 (es) | Anticuerpo monoclonal de interleucina-31 | |
CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
CL2021003535A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019) | |
BRPI0813985A2 (pt) | anticorpos humanos para cd20 humana e método para seu uso. | |
BR112016000666A2 (pt) | Constructos de ligação de antígeno cd3 e cd19 biespecíficos | |
CL2014000590A1 (es) | Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. | |
TR201905458T4 (tr) | Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri. | |
BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
EA201591465A1 (ru) | Специфичные участки для модификации антител для получения иммуноконъюгатов | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
BR112014021081A2 (pt) | anticorpos para a metaloproteinase da matriz 9 | |
CL2007002070A1 (es) | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade | |
BRPI0906478B8 (pt) | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende | |
BR112012022342A2 (pt) | anticorpos monoclonais dirigidos a cd52 | |
ES2656971T3 (es) | Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7 | |
BR112018016367A2 (pt) | anticorpo anti-cd20 canino quimérico | |
AR115053A1 (es) | Anticuerpos para radionúclidos quelados | |
AR086239A1 (es) | Composiciones que comprenden un antimetabolito de glucosa y selenio | |
CL2021000501A1 (es) | Anticuerpos de anti-cd33 y métodos para usarlos. | |
BR112014002406A2 (pt) | método para promoção de higiene e limpeza | |
BR112013000840A2 (pt) | método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial. | |
CL2014000434A1 (es) | Metodo para determinar la presencia o ausencia de un anticuerpo que se enlaza de manera específica a una proteína e (rns) de virus de diarrea viral bovina (bvdv); equipo de diagnostico que comprende los reactivos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |